Brilliant Violet 605™ anti-human CD66a/c/e

Antibodies Single
Sony
ASL-32
Flow Cytometry
Mouse IgG2b, κ
Human
2311615
$170.00

Description

The ASL-32 mAb reacts with an antigen epitope shared by CD66a, c and e. CD66a/c/e are members of the CEA (carcinoembryonic antigen) family of the Ig superfamily. CD66 plays a role in hemophilic and heterophilic adhesion. CD66a, also known as CEACAM1 and BGP (biliary glycoprotein), is mainly expressed on granulocytes, binds to CD66a, c, e, and CD62E. CD66c (known as CEACAM6, NCA) is expressed on granulocytes and epithelial cells. The ligands of CD66c are CD66a-e, CD62E and Galectins. CD66e molecule is also called CEA or CEACAM5, and is primarily found on epithelial cells. CD66e binds to CD66a, c and e.

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

  1. Shey MS, et al. 2012. J Immunol Methods. 376:79. PubMed.